Literature DB >> 28456683

Patchouli alcohol ameliorates dextran sodium sulfate-induced experimental colitis and suppresses tryptophan catabolism.

Chang Qu1, Zhong-Wen Yuan2, Xiu-Ting Yu3, Yan-Feng Huang4, Guang-Hua Yang5, Jian-Nan Chen6, Xiao-Ping Lai7, Zi-Ren Su8, Hui-Fang Zeng9, Ying Xie10, Xiao-Jun Zhang11.   

Abstract

Despite the increased morbidity of ulcerative colitis (UC) in recent years, available treatments remain unsatisfactory. Pogostemon cablin has been widely applied to treat a variety of gastrointestinal disorders in clinic for centuries, in which patchouli alcohol (PA, C15H26O) has been identified as the major active component. This study attempted to determine the bioactivity of PA on dextran sulfate sodium (DSS)-induced mice colitis and clarify the mechanism of action. Acute colitis was induced in mice by 3% DSS for 7 days. The mice were then given PA (10, 20 and 40mg/kg) or sulfasalazine (SASP, 200mg/kg) as positive control via oral administration for 7 days. At the end of study, animals were sacrificed and samples were collected for pathological and other analysis. In addition, a metabolite profiling and a targeted metabolite analysis, based on the Ultra-Performance Liquid Chromatography coupled with mass spectrometry (UPLC-MS) approach, were performed to characterize the metabolic changes in plasma. The results revealed that PA significantly reduced the disease activity index (DAI) and ameliorated the colonic injury of DSS mice. The levels of colonic MPO and cytokines involving TNF-α, IFN-γ, IL-1β, IL-6, IL-4 and IL-10 also declined. Furthermore, PA improved the intestinal epithelial barrier by enhancing the level of colonic expression of the tight junction (TJ) proteins, for instance ZO-1, ZO-2, claudin-1 and occludin, and by elevating the levels of mucin-1 and mucin-2 mRNA. The study also demonstrated that PA inhibited the DSS-induced cell death signaling by modulating the apoptosis related Bax and Bcl-2 proteins and down-regulating the necroptosis related RIP3 and MLKL proteins. By comparison, up-regulation of IDO-1 and TPH-1 protein expression in DSS group was suppressed by PA, which was in line with the declined levels of kynurenine (Kyn) and 5-hydroxytryptophan (5-HTP) in plasma. The therapeutic effect of PA was evidently reduced when Kyn was given to mice. In summary, the study successfully demonstrated that PA ameliorated DSS-induced mice acute colitis by suppressing inflammation, maintaining the integrity of intestinal epithelial barrier, inhibiting cell death signaling, and suppressing tryptophan catabolism. The results provided valuable information and guidance for using PA in treatment of UC.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5-HT (Serotonin, 5-Hydroxytryptamine, PubChem CID: 5202); 5-HTP (5-hydroxy-l-tryptophan, PubChem CID: 846439280); Dextran sodium sulfate; Kynurenine; Kynurenine (PubChem CID: 846); L-tryptophan (PubChem CID: 6305); Patchouli alcohol; Patchouli alcohol (PubChem CID: 10955174); Targeted metabolomics; Tryptophan metabolism; Ulcerative colitis

Mesh:

Substances:

Year:  2017        PMID: 28456683     DOI: 10.1016/j.phrs.2017.04.017

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  19 in total

Review 1.  Biologically active isoquinoline alkaloids covering 2014-2018.

Authors:  Xiao-Fei Shang; Cheng-Jie Yang; Susan L Morris-Natschke; Jun-Cai Li; Xiao-Dan Yin; Ying-Qian Liu; Xiao Guo; Jing-Wen Peng; Masuo Goto; Ji-Yu Zhang; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2020-07-29       Impact factor: 12.944

2.  Linalyl acetate restores colon contractility and blood pressure in repeatedly stressed-ulcerative colitis rats.

Authors:  You Kyoung Shin; Soonho Kwon; Yu Shan Hsieh; A Young Han; Geun Hee Seol
Journal:  Environ Health Prev Med       Date:  2022       Impact factor: 4.395

3.  Patchouli Alcohol: a Natural Sesquiterpene Against Both Inflammation and Intestinal Barrier Damage of Ulcerative Colitis.

Authors:  Zhuona Wu; Hairong Zeng; Lili Zhang; Yiqiong Pu; Suyun Li; Yi Yuan; Tong Zhang; Bing Wang
Journal:  Inflammation       Date:  2020-08       Impact factor: 4.657

4.  Berberrubine attenuates mucosal lesions and inflammation in dextran sodium sulfate-induced colitis in mice.

Authors:  Xiu-Ting Yu; Yi-Fei Xu; Yan-Feng Huang; Chang Qu; Lie-Qiang Xu; Zi-Ren Su; Hui-Fang Zeng; Lin Zheng; Tie-Gang Yi; Hui-Lin Li; Jian-Ping Chen; Xiao-Jun Zhang
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

Review 5.  Therapeutic Potential of Amino Acids in Inflammatory Bowel Disease.

Authors:  Yulan Liu; Xiuying Wang; Chien-An Andy Hu
Journal:  Nutrients       Date:  2017-08-23       Impact factor: 5.717

6.  Astragaloside IV alleviates the symptoms of experimental ulcerative colitis in vitro and in vivo.

Authors:  Suxiao Wu; Zilan Chen
Journal:  Exp Ther Med       Date:  2019-08-16       Impact factor: 2.447

Review 7.  Beneficial effects of nutritional supplements on intestinal epithelial barrier functions in experimental colitis models in vivo.

Authors:  Hilda Vargas-Robles; Karla Fabiola Castro-Ochoa; Alí Francisco Citalán-Madrid; Michael Schnoor
Journal:  World J Gastroenterol       Date:  2019-08-14       Impact factor: 5.742

8.  Translational Potential of Metabolomics on Animal Models of Inflammatory Bowel Disease-A Systematic Critical Review.

Authors:  Lina Almind Knudsen; Rasmus Desdorf; Sören Möller; Signe Bek Sørensen; Axel Kornerup Hansen; Vibeke Andersen
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

Review 9.  Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease.

Authors:  Bei Yue; Zhi-Lun Yu; Cheng Lv; Xiao-Long Geng; Zheng-Tao Wang; Wei Dou
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

10.  Periplaneta americana Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Rats by Keap1/Nrf-2 Activation, Intestinal Barrier Function, and Gut Microbiota Regulation.

Authors:  Xuewei Ma; Yichen Hu; Xin Li; Xiaoting Zheng; Yitao Wang; Jinming Zhang; Chaomei Fu; Funeng Geng
Journal:  Front Pharmacol       Date:  2018-08-22       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.